Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0IALMN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Sacituzumab-Compound (Ia)
|
|||||
| Synonyms |
Sacituzumab Compound (Ia)
Click to Show/Hide
|
|||||
| Organization |
Orum Therapeutics, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Bladder cancer [ICD11:2C94]
Investigative
Triple negative breast cancer [ICD11:2C60-2C65]
Investigative
Urethral cancer [ICD11:2F78]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Sacituzumab
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
NeoDegrader P1
|
Payload Info | ||||
| Therapeutic Target |
Protein cereblon (CRBN)
|
Target Info | ||||
| Linker Name |
Sacituzumab-Compound (Ia) linker
|
|||||
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 23.00 pM | Positive TROP2 expression (TROP2+++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Bladder carcinoma | KMBC-2 cells | CVCL_2977 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 38.50 pM | Positive TROP2 expression (TROP2+++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Bladder carcinoma | SW780 cells | CVCL_1728 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 56.20 pM | Positive TROP2 expression (TROP2+++/++) | ||
| Method Description |
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC2157 cells | CVCL_1261 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.